Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
P/E ratio for Mirati Therapeutics, Inc. (MRTX)
P/E ratio as of 2022: -3.44
According to Mirati Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.44. At the end of 2021 the company had a P/E ratio of -13.08.
P/E ratio history for Mirati Therapeutics, Inc. from 2003 to 2022
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2022 | -3.44 |
| 2021 | -13.08 |
| 2020 | -27.65 |
| 2019 | -22.71 |
| 2018 | -13.32 |
| 2017 | -6.55 |
| 2016 | -1.13 |
| 2015 | -8.28 |
| 2014 | -5.72 |
| 2013 | -3.48 |
| 2012 | -3.45 |
| 2011 | -4.71 |
| 2010 | -0.39 |
| 2009 | -0.23 |
| 2008 | -0.70 |
| 2007 | -0.23 |
| 2006 | -0.62 |
| 2005 | -0.23 |
| 2004 | -0.29 |
| 2003 | -0.55 |